The goals of the Pathology Core are to collect, prioritize, distribute and interrogate both human and mouse models of prostate cancer. The mission of the tissue acquisition component of the Pathology Gore is to: provide a reliable and continuous source of well characterized and annotated prostate tissue samples for evaluation of tumor markers and other studies;minimize investigator efforts needed to obtain human tissues;Improve the quality of human tissues collected from donors after appropriate consent;assure that the tissues meet stated diagnoses;minimize the chances of a diagnostic specimen being compromised by improper handling;foster collaborative efforts between basic scientists and clinicians by providing hands on expertise with all aspects of tissue processing including histology, immunohistochemistry, imaging, etc.;and ensure fair distribution of tissue under the direction of the SPORE Executive Committee. The Core has also constructed microarrays from over 1000 cases of prostate cancer with clinical follow up, including normal and malignant tissues from patients of diverse ethnic backgrounds. The Core collects and annotates diverse specimens including fixed and frozen tumor tissue, tissue mircroarrays, whole mounts, paraffin blocks, fresh tissue serum, plasma, urine, DNA/RNA, and fixed tissues from animal xenografts and GEM models. Services include Veridex CTC enumeration, CTC enumeration and characterization in collaboration with the Tseng lab, quantitative immunohistochemistry, laser microdissection, FISH and double and single immunofluoresence. The Core works closely with clinical investigators to collect, process and examine critical biomarkers associated with those clinical trials. The core provides expertise with diagnosis of prostate neoplasia in biopsies and prostatectomy specimens as well as multiple murine models of prostate cancer. The Core works closely with other SPORE sites to standardize assays of common importance and works closely with the Statistics and Bioinformatics Cores linking tissues to the prostate clinical database and to national tissue banks (CaBIG). The Pathology Core is heavily invested in developing and acquiring new technologies to solve problems related to the procurement and analysis of all pathological specimens.

Public Health Relevance

The pathology core is an essential component of the projects, all of which have a translational arm requiring analysis of human and animal tissues. The Core makes available fresh, frozen, and fixed biopsy and prostatectomy tissues, provides DNA and RNA from cancer and normal tissues, and assists with performing immunohistochemistry, Veridex CTC enumeration, laser capture microscopy, whole slide scanning, and image analysis. The Core also is essential for collaborative research involving evaluation of murine models of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-12
Application #
8760363
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$179,158
Indirect Cost
$75,313
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Henning, Susanne M; Wang, Piwen; Said, Jonathan W et al. (2015) Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate 75:550-9
Apostolova, Liana G; Di, Li Jie; Duffy, Erin L et al. (2014) Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dement Geriatr Cogn Disord 37:315-26
Li, Z; Tseng, C-H; Li, Q et al. (2014) Clinical efficacy of a medically supervised outpatient high-protein, low-calorie diet program is equivalent in prediabetic, diabetic and normoglycemic obese patients. Nutr Diabetes 4:e105
Lin, Millicent; Chen, Jie-Fu; Lu, Yi-Tsung et al. (2014) Nanostructure embedded microchips for detection, isolation, and characterization of circulating tumor cells. Acc Chem Res 47:2941-50
Keto, Christopher J; Aronson, William J; Terris, Martha K et al. (2014) Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol 65:620-7
Hsi, Eric D; Said, Jonathan; Macon, William R et al. (2014) Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol 38:768-75
Wu, Anna M (2014) Engineered antibodies for molecular imaging of cancer. Methods 65:139-47
Garcia, Alejandro J; Ruscetti, Marcus; Arenzana, Teresita L et al. (2014) Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 34:2017-28
Chamie, Karim; Sonn, Geoffrey A; Finley, David S et al. (2014) The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology 83:369-75
Galet, Colette; Gollapudi, Kiran; Stepanian, Sevan et al. (2014) Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res (Phila) 7:97-104

Showing the most recent 10 out of 189 publications